Definium Therapeutics, Inc.

NASDAQ:DFTX

Biotechnology

Healthcare
$29.12 -1.67%

-$0.41 today

Market cap
$3.99B
Beta
2.38
P/E (TTM)
-11.0
EPS (TTM)
-$2.18
52W Low $12.88High $26.15

Volume 1.91M

Average 2.67M

DFTX Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Definium Therapeutics, Inc.NASDAQ: DFTX

Gross Profit · Q3 FY2026 · quarter ended Sep 2026

Gross profit remains negative

Q3 FY2026 gross profit was $0, compared with $0 a year earlier. Trailing-twelve-month gross profit was $0.

Context

  • Gross profit increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly gross profit holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$0— QoQ
Last fiscal yearDec 2025
$0+100.0% YoY
LTMSep 2026
$0— YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
+100.0%

Gross Profit vs competitors

How DFTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
DFTX Competitors
Gross Profit for DFTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AXSMAxsome Therapeutics, Inc.LTM Jun 2026$724.04M USD+59.9%+136.2%93.2%
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026$19M USD+2140.8%—95.0%
ATHEAlterity Therapeutics LimitedFY2025A$5.31M AUD+39.6%+3.7%97.7%
DFTXDefinium Therapeutics, Inc.LTM Sep 2026$0 USD———
NERVMinerva Neurosciences, Inc.LTM Jun 2026$0 USD———
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 2026-$82K USD———
GHRSGH Research PLCLTM Mar 2026-$268K USD———
ANROAlto Neuroscience, Inc.LTM Mar 2026-$284K USD-67.1%——
MPLTMapLight Therapeutics, Inc.LTM Mar 2026-$574K USD-69.3%——
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026-$5.01M USD———
PRAXPraxis Precision Medicines, Inc.LTM Sep 2026-$77.55M USD+67.5%——
Peer median (excluding DFTX) —+49.7%+70.0%95.0%

Competitors are the stored peer set for DFTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue003.16M527K0
Gross Profit00(3.16M)(527K)0
Gross Margin—————
Research & Development34.79M36.17M48.96M65.3M117.67M
Selling, General & Admin59.07M30.16M41.74M38.62M48.64M
Operating Expenses93.85M66.33M90.7M103.39M166.31M
Depreciation & Amortization2.62M3.18M3.16M527K0
EBITDA(91.22M)(52.12M)(92.57M)(105.87M)(178.31M)
EBITDA Margin—————
Operating Income(93.85M)(66.33M)(93.87M)(103.92M)(166.31M)
Operating Margin—————
Interest Income01.5M5.58M11.56M10.96M
Interest Expense359K1.5M920K2.28M5.48M
Other Income / Expenses(339K)9.54M(1.87M)(4.76M)(17.48M)
Income Before Tax(94.19M)(56.8M)(95.73M)(108.68M)(183.79M)
Pre-Tax Margin—————
Income Tax Expense(1.16M)0000
Net Income(93.04M)(56.8M)(95.73M)(108.68M)(183.79M)
Net Margin—————
EPS (Basic)(3.40)(1.53)(2.44)(1.54)(2.06)
EPS (Diluted)(3.40)(1.53)(2.44)(0.15)(2.06)
Weighted Avg Shares27.38M30.86M39.16M70.46M89.33M
Weighted Avg Shares (Diluted)27.38M30.86M39.16M704.61M89.33M

Definium Therapeutics, Inc.

NASDAQ:DFTX

Intrinsic Alpha fair value

Locked

Current Price

$29.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.